NetworkNewsBreaks Archive - Page 1926 of 1993

WednesdayMar 22, 2017 12:22 pm

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Shares Spike on Orphan Drug Designation for Annamycin

Moleculin Biotech (NASDAQ: MBRX) shares are 31% higher mid-morning after the company said it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for Annamycin for the treatment of acute myeloid leukemia (AML). This designation will provide the company several benefits, such as tax credits for qualified clinical trials costs, exemptions from certain FDA application fees, and seven years of market exclusivity upon regulatory product approval. "We are pleased to report this key milestone and the FDA's decision to grant Annamycin orphan drug designation. We look forward to announcing additional milestones in regard to our clinical…

WednesdayMar 22, 2017 11:18 am

NetworkNewsBreaks – TapImmune, Inc. (NASDAQ: TPIV) Announces Participation in Two Upcoming Investor and Industry Conferences

Clinical-stage immuno-oncology company TapImmune, Inc. (NASDAQ: TPIV) today announced plans to participate in two upcoming investor and industry conferences. First, Dr. Glynn Wilson, chairman and CEO of TapImmune, will be offering an overview of the company’s business, clinical pipeline and partnering opportunities for its proprietary PolyStart technology platform at the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York City. Wilson’s presentation is scheduled for 10:35 am ET on Tuesday, March 28, 2017. The full presentation will be webcast live and archived for future viewing at http://tapimmune.com/events. Second, Dr. John Bonfiglio, president and chief operating…

WednesdayMar 22, 2017 10:44 am

NetworkNewsBreaks – UniPixel, Inc. (NASDAQ: UNXL) Defies Market Slump; Shares Rise on Multi-Year Deal with Major PC Maker

Shares of UniPixel (NASDAQ: UNXL) are up more than 16% this morning after the company said it has entered into a long-term agreement with a major U.S.-based PC maker to supply XTouch touch screen sensors for multiple years. Per the agreement, the PC maker will supply rolling forecasts to UniPixel and will use its best commercial efforts to make the purchases outlined in the rolling forecasts. The company will reserve manufacturing capacity for the PC maker based off of the rolling forecasts. The agreement also permits the PC maker to request limited, exclusive early access to certain technology development advancements,…

TuesdayMar 21, 2017 1:24 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 21, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: PULM 25.90% – News: Receives key patent from European Union HTBX 9.68% – News: Releases latest results from phase 2 trial of HS-110 in combination with nivolumab SPYR 9.09% – News: Issues shareholder update SPDL 7.76% – News: Enters digital marketing partnership with Mach One Media Group CATS 6.84% – News: Expands its OnTrak™-C coverage to Texas with leading insurance provider LOTE 5.97% – News: Appoints new CEO, plans first acquisition OWCP 5.38% –…

TuesdayMar 21, 2017 1:10 pm

NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Obtains Patent for Use of CLR 124 in PET Imaging

Cellectar Biosciences (NASDAQ: CLRB) this morning said the United States Patent and Trademark Office has granted a method of use patent for CLR 124, the cancer imaging agent that utilizes the company’s proprietary phospholipid drug conjugate (PDC) delivery platform. The newly issued patent, titled “Phospholipid Ether Analogs as Agents for Detecting and Locating Cancer and Methods Thereof,” provides intellectual property protection through March 2, 2025. The patent outlines the use of CLR 124 in PET imaging to detect radiation-insensitive or chemotherapy-insensitive cancers and cancer metastases. Additionally, the patent provides coverage for the use of CLR 124 in identifying the location…

TuesdayMar 21, 2017 1:04 pm

NetworkNewsBreaks – Celldex Therapeutics, Inc. (NASDAQ: CLDX) Reiterated with “Buy” Rating, $10 PT at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and price target of $10 on shares of Celldex Therapeutics’ (NASDAQ: CLDX) stock. The news follows the company’s report of business and financial highlights for the fourth quarter and year-ended December 31, 2016. The company reported total revenue of $1.9 million in the fourth quarter of 2016, and full-year revenue of $6.8 million, compared to $1.8 million and $5.5 million for the comparable periods in 2015. The company credited the increase in revenue to its clinical trial collaboration with Bristol-Myers Squibb. The company also provided an update on its pipeline, including the increase…

TuesdayMar 21, 2017 12:53 pm

NetworkNewsBreaks – Caladrius Biosciences, Inc. (NASDAQ: CLBS) Receives “Buy” Rating, $15 PT at Aegis Capital

Aegis Capital has issued a ‘Buy’ rating and price target of $15 on shares of Caladrius Biosciences’ (NASDAQ: CLBS) stock. The company recently reported financial results for the three and 12 months ended December 31, 2016. The company full year revenues of $35.3 million, an increase of 57% compared with $22.5 million for 2015. Caladrius also reported cash at year-end of $14.7 million. Additionally, the company recently announced the sale of the remaining 80.1% interest in its PCT LLC subsidiary to Hitachi Chemical for $75 million in cash with an additional $5 million payable upon reaching an undisclosed revenue milestone…

TuesdayMar 21, 2017 12:40 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating, $3 PT on Achaogen, Inc. (NASDAQ: AKAO)

Aegis Capital has reiterated a ‘Buy’ rating and price target of $29 on shares of Achaogen’s (NASDAQ: AKAO) stock. The biopharmaceutical company recently reported financial results for the fourth quarter and year ended December 31, 2016, posting total Q4 contract revenue of $10.7 million, which was less than expected. Analysts cited the company’s uneventful fourth quarter in the report, but mentioned that milestones and catalysts are more important in evaluating clinical-stage development companies. Achaogen also recently released an update on its lead product candidate, Plazomicin, which has shown positive results in two phase 3 clinical trials. The company plans to…

TuesdayMar 21, 2017 11:37 am

NetworkNewsBreaks – CytoDyn Inc.’s (CYDY) PRO 140 Demonstrates Considerable Potential as HIV Treatment

Though considerable advances have been made in the prevention and treatment of HIV/AIDS, more than 1.2 million people in the U.S. are still affected by the disease. CytoDyn Inc.’s (OTCQB: CYDY) PRO 140 candidate is considered one of the most advanced experimental monoclonal antibodies for HIV treatment, and it has been used in more than 140 HIV-positive patients in placebo-controlled and open label FDA-approved clinical trials. “The drug has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test patients and has been designated a ‘fast track’ product candidate…

TuesdayMar 21, 2017 10:37 am

NetworkNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Subsidiary Teams with Planet Payment to Offer Multi-Currency Pricing

Mobile payment technology company Net Element, Inc. (NASDAQ: NETE) this morning announced that its Unified Payments subsidiary has entered into a strategic partnership with Planet Payment, Inc. (NASDAQ: PLPM), a leading provider of international and multi-currency payment processing services. Through this agreement, Unified Payments will offer Planet Payment’s Multi-Currency Pricing to its portfolio of online merchants, enabling them to more effectively expand into foreign markets by displaying pricing and accepting payments in a variety of local currencies. “We are excited to form this partnership with Planet Payment to bring our online merchants the ability to price in multiple currencies and…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks